🚀 VC round data is live in beta, check it out!
ImmuCell Valuation Multiples
Discover revenue and EBITDA valuation multiples for ImmuCell and similar public comparables like OnKure Therapeutics, Kaldvik, Cantourage Group, Paradigm Biopharma and more.
ImmuCell Overview
About ImmuCell
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Founded
1982
HQ
Employees
75
Website
Financials (FY)
EV
$82M
ImmuCell Financials
ImmuCell reported last fiscal year revenue of $28M and EBITDA of $2M.
In the same fiscal year, ImmuCell generated $11M in gross profit, $2M in EBITDA, and had net loss of ($1M).
Revenue (LTM)
ImmuCell P&L
In the most recent fiscal year, ImmuCell reported revenue of $28M and EBITDA of $2M.
ImmuCell expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $28M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $11M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 6% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (4%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ImmuCell Stock Performance
ImmuCell has current market cap of $72M, and enterprise value of $82M.
Market Cap Evolution
ImmuCell's stock price is $7.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82M | $72M | 5.4% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmuCell Valuation Multiples
ImmuCell trades at 3.0x EV/Revenue multiple, and 38.1x EV/EBITDA.
EV / Revenue (LTM)
ImmuCell Financial Valuation Multiples
As of April 18, 2026, ImmuCell has market cap of $72M and EV of $82M.
Equity research analysts estimate ImmuCell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ImmuCell has a P/E ratio of (69.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $72M | XXX | $72M | XXX | XXX | XXX |
| EV (current) | $82M | XXX | $82M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 38.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 49.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.1x | XXX | XXX | XXX |
| P/E | — | XXX | (69.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 66.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ImmuCell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ImmuCell Margins & Growth Rates
ImmuCell's revenue in the last fiscal year grew by 4%.
ImmuCell's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
ImmuCell Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ImmuCell Public Comps
See public comps and valuation multiples for other Agriculture and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ImmuCell | XXX | XXX | XXX | XXX | XXX | XXX |
| OnKure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaldvik | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantourage Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Paradigm Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immutep | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ImmuCell M&A Activity
ImmuCell acquired XXX companies to date.
Last acquisition by ImmuCell was on XXXXXXXX, XXXXX. ImmuCell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ImmuCell
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImmuCell Investment Activity
ImmuCell invested in XXX companies to date.
ImmuCell made its latest investment on XXXXXXXX, XXXXX. ImmuCell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ImmuCell
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ImmuCell
| When was ImmuCell founded? | ImmuCell was founded in 1982. |
| Where is ImmuCell headquartered? | ImmuCell is headquartered in United States. |
| How many employees does ImmuCell have? | As of today, ImmuCell has over 75 employees. |
| Who is the CEO of ImmuCell? | ImmuCell's CEO is Olivier te Boekhorst. |
| Is ImmuCell publicly listed? | Yes, ImmuCell is a public company listed on Nasdaq. |
| What is the stock symbol of ImmuCell? | ImmuCell trades under ICCC ticker. |
| When did ImmuCell go public? | ImmuCell went public in 1987. |
| Who are competitors of ImmuCell? | ImmuCell main competitors are OnKure Therapeutics, Kaldvik, Cantourage Group, Paradigm Biopharma. |
| What is the current market cap of ImmuCell? | ImmuCell's current market cap is $72M. |
| What is the current revenue of ImmuCell? | ImmuCell's last fiscal year revenue is $28M. |
| What is the current EV/Revenue multiple of ImmuCell? | Current revenue multiple of ImmuCell is 3.0x. |
| Is ImmuCell profitable? | No, ImmuCell is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.